The real-world study of the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer in China

被引：0

作者：

Cui Jiujie ^{[1
]}

Fu Qihan ^{[2
]}

Chen Xiaobing ^{[3
]}

Wang Yanling ^{[1
]}

Li Qi ^{[4
]}

Wang Feng ^{[5
]}

Li Zhihua ^{[6
]}

Dai Guanghai ^{[7
]}

Wang Yusheng ^{[8
]}

Zhang Hongmei ^{[9
]}

Liang Houjie ^{[10
]}

Zhou Jun ^{[11
,12
]}

Yang Liu ^{[13
]}

Wang Fenghua ^{[14
]}

Zheng Leizhen ^{[15
]}

Chen Xiaofeng ^{[16
]}

Gong Ping ^{[17
]}

Liu Jiang ^{[18
]}

Yuan Ying ^{[19
]}

Wang Lin ^{[20
]}

Cheng Yuejuan ^{[21
]}

Zhang Jun ^{[22
]}

Zhou Yuhong ^{[23
]}

Guo Weijian ^{[24
]}

Zhan Xianbao ^{[25
]}

Zou Zhengyun ^{[26
]}

Li Da ^{[27
]}

Zeng Shan ^{[28
]}

Li Enxiao ^{[29
]}

Li Zhiwei ^{[30
]}

Teng Zan ^{[31
]}

Cao Dan ^{[32
]}

Kan Jie ^{[33
]}

Xiong Jianping ^{[34
]}

Quan Ming ^{[35
]}

Yao Jiayu ^{[1
]}

Yang Haiyan ^{[1
]}

Wang Liwei ^{[1
]}

机构：

[1] Department of Medical Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

[2] Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

[3] Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China

[4] Department of Medical Oncology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China

[5] Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

[6] Department of Medical Oncology, Sun Yat-sen Medical Hospital Sun Yat-sen University, Guangzhou, China

[7] Medical Oncology, Chinese PLA General Hospital, Beijing, China

[8] Department of Gastrointestinal Oncology, Shanxi Provincial Cancer Hospital, Affiliated to Shanxi Medical University, Taiyuan, China

[9] Department of Clinical Oncology, Xijing Hospital, Air Force Medical University, Xi’an, China

[10] Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Military Medical University), Chongqing, China

[11] Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Peking University Cancer Hospital &amp

[12] Institute, Beijing, China

[13] Cancer Center, Department of Medical Oncology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China

[14] Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China

[15] Oncology Department, Xin Hua Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, China

[16] Department of Oncology, the First Affiliated Hospital with Nanjing Medical University, Nanjing, China

[17] Department of Oncology, The First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, China

[18] Department of Oncology, People’s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang, China

[19] Department of Medical Oncology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China

[20] Department of Medical Oncology, Hainan Genderal Hospital, Haikou, China

[21] Division of Medical Oncology, Peking Union Medical College Hospital, Beijing, China

[22] Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

[23] Department of Medical Oncology, Shanghai Zhongshan Hospital, Fudan University, Shanghai, China

[24] Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China

[25] Department of Medical Oncology, Changhai Hospital of Shanghai, Navy Medical University, Shanghai, China

[26] Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing, China

[27] Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, China

[28] Department of Medical Oncology, Xiangya Hospital Central South University, Changsha, China

[29] Department of Medical Oncology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

[30] Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China

[31] Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China

[32] Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, China

[33] Department of Medical Oncology, Qinghai Provincial People’s Hospital, Xi’ning, China

[34] Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China

[35] Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai,

来源：

胰腺病学杂志（英文） | 2024年 / 07卷 / 01期

关键词：

Advanced pancreatic cancer; China Pancreas Data Center; Chinese; First-line regimens; Real-world study;

D O I：

暂无

中图分类号：

R735.9 [胰腺肿瘤];

学科分类号：

摘要：

Objective: Real-world diagnostic and treatment data for pancreatic cancer in China are lacking. As such, the present study investigated the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer (including locally advanced and metastatic disease) in the Hospital-based Advanced Pancreatic Cancer Cohort in China of the China Pancreas Data Center database.Methods: A total of 5349 Chinese patients with advanced pancreatic cancer were identified from a database. The entire course of real-world pancreatic cancer management was analyzed.Results: The proportion of patients with advanced pancreatic cancer was higher among males than females (62.4% vs 37.6%, respectively). Patients typically had a history of hypertension (30.8%), diabetes (21.6%), and cholangitis (20.2%). Abdominal pain (51.6%), abdominal distension (27.1%), jaundice (20.1%), and weight loss (16.3%) were the main symptoms observed in patients with advanced pancreatic cancer in this cohort. Serum carbohydrate antigen (CA)19-9 is one of the most common tumor markers. In the present study, 2562 patients underwent first-line therapy. The median progression-free survival (PFS) for patients undergoing first-line therapy was 4.1 months. The major options for first-line therapy included gemcitabine (GEM) plus S-1 (GS/X) (23.4%), nab-paclitaxel plus GEM (AG) (18.1%), oxaliplatin, irinotecan, and leucovorin-modulated fluorouracil (FOLFIRINOX; 11.9%), nab-paclitaxel plus S-1 (AS) (8.9%), and GEM combined with oxaliplatin/cisplatin (GEMOX/GP) (7.6%). The AS and GS/X regimens were associated with the highest PFS rates.Conclusion: This is the first study to report multicenter, real-world data regarding advanced pancreatic cancer in China. Results revealed that real-world treatment options differed from guideline recommendations, and PFS was shorter than that in previously reported data. Improving intelligent follow-up systems and standardizing diagnosis and treatment of pancreatic cancer is recommended.

引用

共 58 条

[41] Pathology and Molecular Genetics of Pancreatic Neoplasms
Wood, Laura D.
Hruban, Ralph H.
[J]. CANCER JOURNAL, 2012, 18 (06) : 492 - 501
[42] Familial pancreatic cancer and hereditary syndromes: screening strategy for high-risk individuals
Matsubayashi, Hiroyuki
[J]. JOURNAL OF GASTROENTEROLOGY, 2011, 46 (11) : 1249 - 1259
[43] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, Thierry
Desseigne, Francoise
Ychou, Marc
Bouche, Olivier
Guimbaud, Rosine
Becouarn, Yves
Adenis, Antoine
Raoul, Jean-Luc
Gourgou-Bourgade, Sophie
de la Fouchardiere, Christelle
Bennouna, Jaafar
Bachet, Jean-Baptiste
Khemissa-Akouz, Faiza
Pere-Verge, Denis
Delbaldo, Catherine
Assenat, Eric
Chauffert, Bruno
Michel, Pierre
Montoto-Grillot, Christine
Ducreux, Michel
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) : 1817 - 1825
[44] Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205
Philip, Philip A.
Benedetti, Jacqueline
Corless, Christopher L.
Wong, Ralph
O'Reilly, Eileen M.
Flynn, Patrick J.
Rowland, Kendrith M.
Atkins, James N.
Mirtsching, Barry C.
Rivkin, Saul E.
Khorana, Alok A.
Goldman, Bryan
Fenoglio-Preiser, Cecilia M.
Abbruzzese, James L.
Blanke, Charles D.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (22) : 3605 - 3610
[45] Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Kindler, Hedy Lee
Niedzwiecki, Donna
Hollis, Donna
Sutherland, Susan
Schrag, Deborah
Hurwitz, Herbert
Innocenti, Federico
Mulcahy, Mary Frances
O'Reilly, Eileen
Wozniak, Timothy F.
Picus, Joel
Bhargava, Pankaj
Mayer, Robert J.
Schilsky, Richard L.
Goldberg, Richard M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (22) : 3617 - 3622
[46] Tobacco and the risk of pancreatic cancer: a review and meta-analysis
Iodice, Simona
Gandini, Sara
Maisonneuve, Patrick
Lowenfels, Albert B.
[J]. LANGENBECKS ARCHIVES OF SURGERY, 2008, 393 (04) : 535 - 545
[47] Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer:: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
Herrmann, Richard
Bodoky, Gyoergy
Ruhstaller, Thomas
Glimelius, Bengt
Bajetta, Emilio
Schueller, Johannes
Saletti, Piercarlo
Bauer, Jean
Figer, Arie
Pestalozzi, Bernhard
Koehne, Claus-Henning
Mingrone, Walter
Stemmer, Salomon M.
Tamas, Karin
Kornek, Gabriela V.
Koeberle, Dieter
Cina, Susanne
Bernhard, Juerg
Dietrich, Daniel
Scheithauer, Werner
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (16) : 2212 - 2217
[48] Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Moore, Malcolm J.
Goldstein, David
Hamm, John
Figer, Arie
Hecht, Joel R.
Gallinger, Steven
Au, Heather J.
Murawa, Pawel
Walde, David
Wolff, Robert A.
Campos, Daniel
Lim, Robert
Ding, Keyue
Clark, Gary
Voskoglou-Nomikos, Theodora
Ptasynski, Mieke
Parulekar, Wendy
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) : 1960 - 1966
[49] Worldwide Burden of; Risk Factors for; and Trends in Pancreatic Cancer.[J].Huang Junjie;Lok Veeleah;Ngai Chun Ho;Zhang Lin;Yuan Jinqiu;Lao Xiang Qian;Ng Kelvin;Chong Charing;Zheng Zhi Jie;Wong Martin CS..Gastroenterology.2020, 3
[50] Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer.[J].Dreyer Stephan B.;Upstill Goddard Rosie;Paulus Hock Viola;Paris Clara;Lampraki Eirini Maria;Dray Eloise;Serrels Bryan;Caligiuri Giuseppina;Rebus Selma;Plenker Dennis;Galluzzo Zachary;Brunton Holly;Cunningham Richard;Tesson Mathias;Nourse Craig;Bailey Ulla Maja;Jones Marc;Moran Jones Kim;Chang David K..Gastroenterology.2020, 1

← 1 2 3 4 5 6 →